Artelo Biosciences, Inc. Common Stock

ARTLNASDAQUSD
1.39 USD
0.04 (2.80%)🟢LIVE (AS OF 01:37 PM EDT)
🟢Market: OPEN
Open?$1.39
High?$1.44
Low?$1.37
Prev. Close?$1.43
Volume?165.2K
Avg. Volume?2.1M
VWAP?$1.39
Rel. Volume?0.08x
Bid / Ask
Bid?$1.20 × 100
Ask?$1.42 × 100
Spread?$0.22
Midpoint?$1.31
Valuation & Ratios
Market Cap?5.0M
Shares Out?3.5M
Float?764.4K
Float %?81.5%
P/E Ratio?N/A
P/B Ratio?0.75
EPS?-$3.86
Dividend?0.00%
Ex-Dividend?N/A

Shares of Artelo Biosciences, Inc. Common Stock (ARTL) are trading at $1.39. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 4, 2026.

News
Profile
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Employees
7
Market Cap
5.1M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2015-10-13
Address
505 LOMAS SANTA FE, SUITE 160
SOLANA BEACH, CA 92075
Phone: 858-925-7049
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-2/3)
Medium-Term (Wave)? Bearish(-1/3)
Short-Term (Ripple)? Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
91
Piotroski F-Score?0/9Weak
Altman Z-Score?-9.51Distress
Confidence?40%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?4.95%Low
Short Interest?37.9K
Days to Cover?1.0
Free Float764.4K
Avg Daily Volume871.3K
Settlement Date2026-05-15
Financial Health
Current Ratio?1.79Adequate
Quick Ratio?1.79Adequate
Cash Ratio?1.76Strong
Debt/Equity?0.07Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A
P/B?
Peers
100
S&P
97
0.75CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
Peers
100
S&P
97
0.4CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-201.8%WEAK
ROA?
S&P
3
-107.6%WEAK
Cash Flow & Enterprise
FCF?$-8364000
Enterprise Value?$-4818678
Fundamentals ratios updated end of day